BMS 986458
Alternative Names: BCL6 LDD; BMS-986458Latest Information Update: 08 Dec 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 04 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06090539)
- 19 Oct 2023 Bristol-Myers Squibb plans a phase-I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy, Combination therapy) in Netherlands and USA (PO) (NCT06090539)
- 30 Sep 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT06090539)